<DOC>
	<DOCNO>NCT02191930</DOCNO>
	<brief_summary>The purpose trial determine 1 . Objective response rate ( ORR ) , define proportion patient CR , CRr PR centrally review restaging six cycle chemotherapy 2 . Progression-free survival ( PFS ) 3 year registration</brief_summary>
	<brief_title>Brentuximab Vedotin B-CAP Treatment Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Criteria ( BCAP ) : classical Hodgkin Lymphoma Age 60 year old ECOG performance status ≤ 2 ≤ 3 due HL CIRSG score ≤ 6 ≤ 3 per organ system ( except score 4 eye , ear , nose throat ) Advanced stage : Stage IIB large mediastinal mass and/or extranodal lesion , stage III IV disease write informed consent Exclusion Criteria ( BCAP ) : Composite lymphoma nodular lymphocyte predominant Hodgkin lymphoma ( NLPHL ) Prior chemotherapy radiation HL except prephase Peripheral neuropathy great CTC Grade 1 Inclusion Criteria ( BV ) : classical Hodgkin Lymphoma Age 60 year old stage IA IVB CIRSG score ≥ 7 4 one organ system ( except score 4 eye , ear , nose throat ) Patients eligible curative polychemotherapy investigator judgment write informed consent Exclusion Criteria ( BV ) : Composite lymphoma nodular lymphocyte predominant Hodgkin lymphoma ( NLPHL ) Prior chemotherapy radiation HL except prephase outline protocol Peripheral neuropathy great CTC Grade 1</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>